Epigenetic markers of colorectal cancers and diagnostic methods using the same

The present invention relates generally to nucleic acid molecules in respect of which changes to DNA methylation levels are indicative of the onset or predisposition to the onset of a neoplasm. More particularly, the present invention is directed to nucleic acid molecules in respect of which changes...

Full description

Saved in:
Bibliographic Details
Main Authors Mitchell, Susan Margaret, Duesing, Konsta Rainer, Buckley, Michael, Xu, Zheng-Zhou, Molloy, Peter Laurence, Ross, Jason Peter, Drew, Horace
Format Patent
LanguageEnglish
Published 26.05.2022
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention relates generally to nucleic acid molecules in respect of which changes to DNA methylation levels are indicative of the onset or predisposition to the onset of a neoplasm. More particularly, the present invention is directed to nucleic acid molecules in respect of which changes to DNA methylation levels are indicative of the onset and/or progression of a large intestine neoplasm, such as an adenoma or adenocarcinoma. The DNA methylation status of the present invention is useful in a range of applications including, but not limited to, those relating to the diagnosis and/or monitoring of colorectal neoplasms, such as colorectal adenocarcinomas. Accordingly, in a related aspect the present invention is directed to a method of screening for the onset, predisposition to the onset and/or progression of a neoplasm by screening for modulation in DNA methylation of one or more nucleic acid molecules.
Bibliography:Application Number: AU20200202747